Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Wall Street Week: Concerns About Tariffs and Hope on Cancer
Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
FiercePharma12d
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Pfizer's CEO, Albert Bourla, Ph.D., has attempted to downplay the investor threat. At the J.P. Morgan Healthcare Conference ...
MRNA, PFE, BNTX: Pharma Stocks Fall as RFK Jr. Set to Become U.S. Health Secretary
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Pfizer CEO: Our stock is very cheap with lots of upside potential
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...